Remission & chronicity
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.
ADRB1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| PROPAFENONE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| ISOPROTERENOL | ↑ activates | Mechanistic | DGIdb | |
| PINDOLOL | ↓ inhibits | Mechanistic | DGIdb | |
| OXPRENOLOL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| CARVEDILOL PHOSPHATE | ↓ inhibits | Mechanistic | DGIdb | |
| BRL35135 | ? unclear | Mechanistic | DGIdb | |
| BUCINDOLOL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| FENOTEROL | ↑ activates | Mechanistic | DGIdb | |
| ESMOLOL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| DILEVALOL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| BUPRANOLOL | ↓ inhibits | Mechanistic | DGIdb | |
| ALPRENOLOL | ? unclear | Mechanistic | 4.88 nM (IC50) | DGIdb |
| LEVOBUNOLOL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| CARTEOLOL | ? unclear | Mechanistic | 1.9 nM (Ki) | DGIdb |
| TERBUTALINE | ↑ activates | Mechanistic | DGIdb | |
| ESMOLOL | ↓ inhibits | Mechanistic | DGIdb | |
| TIMOLOL | ↓ inhibits | Mechanistic | DGIdb | |
| FLECAINIDE ACETATE | ? unclear | Mechanistic | DGIdb | |
| OXPRENOLOL | ? unclear | Mechanistic | DGIdb | |
| DESIPRAMINE | ? unclear | Mechanistic | DGIdb | |
| ISOETHARINE | ? unclear | Mechanistic | DGIdb | |
| LEVOBETAXOLOL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| BETAXOLOL | ↓ inhibits | Mechanistic | 37.1 nM (IC50) | DGIdb |
| ATENOLOL | ↓ inhibits | Mechanistic | DGIdb | |
| BISOPROLOL | ↓ inhibits | Mechanistic | DGIdb | |
| EPINEPHRINE | ↑ activates | Mechanistic | DGIdb | |
| EPINEPHRINE BITARTRATE | ↑ activates | Mechanistic | DGIdb | |
| NOREPINEPHRINE | ↑ activates | Mechanistic | DGIdb | |
| BEVANTOLOL | ? unclear | Mechanistic | DGIdb | |
| ICI-89406 | ↓ inhibits | Mechanistic | DGIdb | |
| LANDIOLOL | ↓ inhibits | Mechanistic | DGIdb | |
| 7-METHYLCYANOPINDOLOL | ↓ inhibits | Mechanistic | DGIdb | |
| PRACTOLOL | ↓ inhibits | Mechanistic | DGIdb | |
| ANISODINE | ? unclear | Mechanistic | DGIdb | |
| DICHLOROISOPROTERENOL | ? unclear | Mechanistic | DGIdb | |
| CARTEOLOL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| HYDROXYAMPHETAMINE HYDROBROMIDE | ↑ activates | Mechanistic | DGIdb | |
| DRONEDARONE | ? unclear | Mechanistic | DGIdb | |
| CIMATEROL | ↑ activates | Mechanistic | DGIdb | |
| CARAZOLOL | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 324 agents ranked by evidence tier.
CD14
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| TISOTUMAB VEDOTIN | ~ modulates | Mechanistic | DGIdb | |
| MORAB-066 | ? unclear | Mechanistic | DGIdb | |
| ANTI-TF MONOCLONAL ANTIBODY ALT-836 | ? unclear | Mechanistic | DGIdb | |
| ANPOCOGIN | ? unclear | Mechanistic | DGIdb | |
| SIMVASTATIN | ? unclear | Mechanistic | DGIdb | |
| CHEMBL377280 | ↓ inhibits | Mechanistic | 43.0 nM (IC50) | ChEMBL |
| CHEMBL203668 | ↓ inhibits | Mechanistic | 170.0 nM (IC50) | ChEMBL |
| CHEMBL202883 | ↓ inhibits | Mechanistic | 63.0 nM (IC50) | ChEMBL |
| CHEMBL204800 | ↓ inhibits | Mechanistic | 240.0 nM (IC50) | ChEMBL |
| CHEMBL381678 | ↓ inhibits | Mechanistic | 1600.0 nM (IC50) | ChEMBL |
| CHEMBL201514 | ↓ inhibits | Mechanistic | 600.0 nM (IC50) | ChEMBL |
| CHEMBL381881 | ↓ inhibits | Mechanistic | 110.0 nM (IC50) | ChEMBL |
| CHEMBL201853 | ↓ inhibits | Mechanistic | 92.0 nM (IC50) | ChEMBL |
| CHEMBL382573 | ↓ inhibits | Mechanistic | 16.0 nM (IC50) | ChEMBL |
| CHEMBL205123 | ↓ inhibits | Mechanistic | 20.0 nM (IC50) | ChEMBL |
| CHEMBL381740 | ↓ inhibits | Mechanistic | 16.0 nM (IC50) | ChEMBL |
| CHEMBL1162921 | ↓ inhibits | Mechanistic | 380.0 nM (IC50) | ChEMBL |
| CHEMBL202399 | ↓ inhibits | Mechanistic | 590.0 nM (IC50) | ChEMBL |
| CHEMBL381021 | ↓ inhibits | Mechanistic | 180.0 nM (IC50) | ChEMBL |
| CHEMBL201901 | ↓ inhibits | Mechanistic | 31.0 nM (IC50) | ChEMBL |
| CHEMBL371638 | ↓ inhibits | Mechanistic | 27.0 nM (IC50) | ChEMBL |
| CHEMBL204084 | ↓ inhibits | Mechanistic | 17.0 nM (IC50) | ChEMBL |
| CHEMBL189175 | ↓ inhibits | Mechanistic | 180.0 nM (IC50) | ChEMBL |
| CHEMBL204231 | ↓ inhibits | Mechanistic | 150.0 nM (IC50) | ChEMBL |
| CHEMBL382807 | ↓ inhibits | Mechanistic | 47.0 nM (IC50) | ChEMBL |
| CHEMBL381897 | ↓ inhibits | Mechanistic | 570.0 nM (IC50) | ChEMBL |
| CHEMBL381896 | ↓ inhibits | Mechanistic | 210.0 nM (IC50) | ChEMBL |
| CHEMBL201835 | ↓ inhibits | Mechanistic | 130.0 nM (IC50) | ChEMBL |
| CHEMBL202505 | ↓ inhibits | Mechanistic | 120.0 nM (IC50) | ChEMBL |
| CHEMBL382572 | ↓ inhibits | Mechanistic | 48.0 nM (IC50) | ChEMBL |
| CHEMBL204602 | ↓ inhibits | Mechanistic | 290.0 nM (IC50) | ChEMBL |
| CHEMBL204858 | ↓ inhibits | Mechanistic | 190.0 nM (IC50) | ChEMBL |
| CHEMBL383717 | ↓ inhibits | Mechanistic | 97.0 nM (IC50) | ChEMBL |
| CHEMBL204654 | ↓ inhibits | Mechanistic | 67.0 nM (IC50) | ChEMBL |
| CHEMBL380534 | ↓ inhibits | Mechanistic | 36.0 nM (IC50) | ChEMBL |
| CHEMBL204653 | ↓ inhibits | Mechanistic | 73.0 nM (IC50) | ChEMBL |
| CHEMBL381156 | ↓ inhibits | Mechanistic | 2400.0 nM (IC50) | ChEMBL |
| CHEMBL438808 | ↓ inhibits | Mechanistic | 130.0 nM (IC50) | ChEMBL |
| CHEMBL377082 | ↓ inhibits | Mechanistic | 4.0 nM (Ki) | ChEMBL |
| CHEMBL206387 | ↓ inhibits | Mechanistic | 2.0 nM (Ki) | ChEMBL |
Showing top 40 of 155 agents ranked by evidence tier.
HMGB1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CHLORAMPHENICOL | ? unclear | Mechanistic | DGIdb | |
| GP100 ANTIGEN | ? unclear | Mechanistic | DGIdb | |
| ANTIBIOTIC | ? unclear | Mechanistic | DGIdb | |
| SODIUM CHLORIDE | ? unclear | Mechanistic | DGIdb | |
| EPIGALLOCATECHIN GALLATE | ? unclear | Mechanistic | DGIdb | |
| AMPICILLIN (ANHYDROUS) | ? unclear | Mechanistic | DGIdb | |
| CISPLATIN | ? unclear | Mechanistic | DGIdb | |
| BIFONAZOLE | ↓ inhibits | Mechanistic | DGIdb | |
| CD24FC | ↓ inhibits | Mechanistic | DGIdb | |
| ADJUVANT | ? unclear | Mechanistic | DGIdb | |
| HEXAMETHYLENE BISACETAMIDE | ? unclear | Mechanistic | DGIdb | |
| SULFURIC ACID | ? unclear | Mechanistic | DGIdb | |
| DNA INTERCALATING AGENT | ? unclear | Mechanistic | DGIdb | |
| STALLIMYCIN | ? unclear | Mechanistic | DGIdb | |
| UREA | ? unclear | Mechanistic | DGIdb | |
| THERAPEUTIC AUTOLOGOUS DENDRITIC CELLS | ? unclear | Mechanistic | DGIdb | |
| ITRACONAZOLE | ? unclear | Mechanistic | DGIdb | |
| PREDNISOLONE | ? unclear | Mechanistic | DGIdb | |
| MELANOMA ANTIGEN RECOGNIZED BY T-CELLS 1 | ? unclear | Mechanistic | DGIdb | |
| GLYCYRRHIZIN | ↓ inhibits | Mechanistic | 87000.0 nM (Kd) | ChEMBL |
| METHOTREXATE | ↓ inhibits | Mechanistic | 24.0 nM (Kd) | ChEMBL |
| SALICYLIC ACID | ↓ inhibits | Mechanistic | 1000.0 nM (Kd) | ChEMBL |
| CHEMBL4129393 | ↓ inhibits | Mechanistic | 1.48 nM (Kd) | ChEMBL |
| CHEMBL4867183 | ↓ inhibits | Mechanistic | 800.0 nM (Kd) | ChEMBL |
| CHEMBL4858896 | ↓ inhibits | Mechanistic | 8600.0 nM (Kd) | ChEMBL |
| CHEMBL4860199 | ↓ inhibits | Mechanistic | 5800.0 nM (Kd) | ChEMBL |
| CHEMBL4864623 | ↓ inhibits | Mechanistic | 26200.0 nM (Kd) | ChEMBL |
| CHEMBL4850898 | ↓ inhibits | Mechanistic | 9900.0 nM (Kd) | ChEMBL |
| CHEMBL4875121 | ↓ inhibits | Mechanistic | 800.0 nM (Kd) | ChEMBL |
| CHEMBL4853073 | ↓ inhibits | Mechanistic | 22000.0 nM (Kd) | ChEMBL |
| CHEMBL4858278 | ↓ inhibits | Mechanistic | 1900.0 nM (Kd) | ChEMBL |
| CHEMBL4853693 | ↓ inhibits | Mechanistic | 14000.0 nM (Kd) | ChEMBL |
| CHEMBL5653589 | ↓ inhibits | Mechanistic | 50.34 nM (Kd) | ChEMBL |
| CHEMBL3752910 | ↓ inhibits | Mechanistic | 3008.4 nM (Kd) | ChEMBL |
| CHEMBL6145593 | ↓ inhibits | Mechanistic | 12500.0 nM (Kd) | ChEMBL |
| ASPIRIN | ↓ inhibits | Mechanistic | 1000.0 nM (Kd) | ChEMBL |
| DIFLUNISAL | ↓ inhibits | Mechanistic | 16000.0 nM (Kd) | ChEMBL |
| CHEMBL113835 | ↓ inhibits | Mechanistic | 900.0 nM (Kd) | ChEMBL |
| CHEMBL114721 | ↓ inhibits | Mechanistic | 1200.0 nM (Kd) | ChEMBL |
| ISOQUERCETIN | ↓ inhibits | Mechanistic | 100.0 nM (Kd) | ChEMBL |
Showing top 40 of 45 agents ranked by evidence tier.
IL1B
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| METFORMIN | ? unclear | Mechanistic | DGIdb | |
| NICARDIPINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| CANAKINUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| TT-301 | ? unclear | Mechanistic | DGIdb | |
| LITHIUM CATION | ? unclear | Mechanistic | DGIdb | |
| THYROGLOBULIN | ? unclear | Mechanistic | DGIdb | |
| LUTIKIZUMAB | ? unclear | Mechanistic | DGIdb | |
| CEFACLOR ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| CLODRONIC ACID | ? unclear | Mechanistic | DGIdb | |
| CELASTROL | ? unclear | Mechanistic | DGIdb | |
| ACITRETIN | ? unclear | Mechanistic | DGIdb | |
| RESVERATROL | ? unclear | Mechanistic | DGIdb | |
| INFLIXIMAB | ? unclear | Mechanistic | DGIdb | |
| PENTAMIDINE | ? unclear | Mechanistic | DGIdb | |
| DRUGSATFDA.NDA:008378 | ? unclear | Mechanistic | DGIdb | |
| RILONACEPT | ↓ inhibits | Mechanistic | DGIdb | |
| USTEKINUMAB | ? unclear | Mechanistic | DGIdb | |
| BECLOMETHASONE DIPROPIONATE | ? unclear | Mechanistic | DGIdb | |
| DIACETYLRHEIN | ? unclear | Mechanistic | DGIdb | |
| RISEDRONIC ACID | ? unclear | Mechanistic | DGIdb | |
| HYDROCORTISONE BUTYRATE | ? unclear | Mechanistic | DGIdb | |
| ECHINACEA EXTRACT | ? unclear | Mechanistic | DGIdb | |
| CHINESE HERBS | ? unclear | Mechanistic | DGIdb | |
| ETIDRONIC ACID | ? unclear | Mechanistic | DGIdb | |
| OFLOXACIN | ? unclear | Mechanistic | DGIdb | |
| CYTARABINE | ? unclear | Mechanistic | DGIdb | |
| CDP-484 | ↓ inhibits | Mechanistic | DGIdb | |
| ERYTHROMYCIN | ? unclear | Mechanistic | DGIdb | |
| THERAPEUTIC MELATONIN | ? unclear | Mechanistic | DGIdb | |
| PRAVASTATIN SODIUM | ? unclear | Mechanistic | DGIdb | |
| GALLIUM NITRATE | ? unclear | Mechanistic | DGIdb | |
| PENTOXIFYLLINE | ? unclear | Mechanistic | DGIdb | |
| ANTIDEPRESSANT AGENT | ? unclear | Mechanistic | DGIdb | |
| VERAPAMIL | ? unclear | Mechanistic | DGIdb | |
| TETRADECANOYLPHORBOL ACETATE | ? unclear | Mechanistic | DGIdb | |
| HYDROQUINONE | ? unclear | Mechanistic | DGIdb | |
| RALOXIFENE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| ANTICONVULSANT AGENT | ? unclear | Mechanistic | DGIdb | |
| NIMUSTINE | ? unclear | Mechanistic | DGIdb | |
| POLYVALENT VACCINE | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 216 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CLAZAKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| MIDOSTAURIN | ? unclear | Mechanistic | DGIdb | |
| ECHINACEA EXTRACT | ? unclear | Mechanistic | DGIdb | |
| NELFINAVIR | ? unclear | Mechanistic | DGIdb | |
| SELECTIVE ESTROGEN RECEPTOR MODULATOR | ? unclear | Mechanistic | DGIdb | |
| SIGNAL TRANSDUCTION INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| OLOKIZUMAB | ? unclear | Mechanistic | DGIdb | |
| IBUDILAST | ? unclear | Mechanistic | DGIdb | |
| VITAMIN A PALMITATE | ? unclear | Mechanistic | DGIdb | |
| IFOSFAMIDE | ? unclear | Mechanistic | DGIdb | |
| SITAGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| METRONIDAZOLE | ? unclear | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2A | ? unclear | Mechanistic | DGIdb | |
| PACIBEKITUG | ↓ inhibits | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| SIRUKUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| HMG-COA REDUCTASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| SAFINGOL | ? unclear | Mechanistic | DGIdb | |
| ENZYME INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| CISPLATIN | ? unclear | Mechanistic | DGIdb | |
| GALLIUM NITRATE | ? unclear | Mechanistic | DGIdb | |
| RITUXIMAB | ? unclear | Mechanistic | DGIdb | |
| INFLIXIMAB | ? unclear | Mechanistic | DGIdb | |
| C326 | ? unclear | Mechanistic | DGIdb | |
| GEMFIBROZIL | ? unclear | Mechanistic | DGIdb | |
| ZILTIVEKIMAB | ? unclear | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ? unclear | Mechanistic | DGIdb | |
| OSIMERTINIB | ? unclear | Mechanistic | DGIdb | |
| BINETRAKIN | ? unclear | Mechanistic | DGIdb | |
| ALOGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| TENELIGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| CHINESE HERBS | ? unclear | Mechanistic | DGIdb | |
| TOCILIZUMAB | ? unclear | Mechanistic | DGIdb | |
| LINAGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| DOCETAXEL ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| VILDAGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| LINEZOLID | ? unclear | Mechanistic | DGIdb | |
| SELENIUM | ? unclear | Mechanistic | DGIdb | |
| SAQUINAVIR | ? unclear | Mechanistic | DGIdb | |
| PAREGORIC | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 181 agents ranked by evidence tier.
NR3C1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| METHYLPREDNISOLONE | ↑ activates | Mechanistic | DGIdb | |
| FOSDAGROCORAT | ↑ activates | Mechanistic | DGIdb | |
| ZK216348 | ↑ activates | Mechanistic | DGIdb | |
| PHENYLMERCURIC ACETATE | ? unclear | Mechanistic | DGIdb | |
| TNF-ALPHA | ? unclear | Mechanistic | DGIdb | |
| HYDROCORTAMATE HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| TRIAMCINOLONE | ↑ activates | Mechanistic | DGIdb | |
| BUDESONIDE | ↑ activates | Mechanistic | DGIdb | |
| ANTICONVULSANT AGENT | ? unclear | Mechanistic | DGIdb | |
| FLUTICASONE FUROATE | ↑ activates | Mechanistic | DGIdb | |
| METHYLPREDNISOLONE ACETATE | ↑ activates | Mechanistic | DGIdb | |
| DAGROCORAT | ↑ activates | Mechanistic | DGIdb | |
| MIFEPRISTONE | ↓ inhibits | Mechanistic | 0.24 nM (Ki) | DGIdb |
| TESTOSTERONE PROPIONATE | ? unclear | Mechanistic | DGIdb | |
| FLURANDRENOLIDE | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1915271 | ? unclear | Mechanistic | DGIdb | |
| CHRYSIN | ? unclear | Mechanistic | DGIdb | |
| FLUOXYMESTERONE | ? unclear | Mechanistic | DGIdb | |
| LOTEPREDNOL | ↑ activates | Mechanistic | DGIdb | |
| DIFLUPREDNATE | ↑ activates | Mechanistic | DGIdb | |
| CORT 108297 | ↓ inhibits | Mechanistic | DGIdb | |
| PROGESTERONE | ? unclear | Mechanistic | 30.5 nM (Ki) | DGIdb |
| BETAMETHASONE SODIUM PHOSPHATE | ↑ activates | Mechanistic | DGIdb | |
| ANTIDEPRESSANT AGENT | ? unclear | Mechanistic | DGIdb | |
| HYDROCORTISONE BUTYRATE | ↑ activates | Mechanistic | DGIdb | |
| VELSECORAT | ↑ activates | Mechanistic | DGIdb | |
| FLUMETHASONE PIVALATE | ↑ activates | Mechanistic | DGIdb | |
| AMCINONIDE | ↑ activates | Mechanistic | DGIdb | |
| CYPROTERONE ACETATE | ↓ inhibits | Mechanistic | DGIdb | |
| C108297 | ↑ activates | Mechanistic | DGIdb | |
| COMPOUND 17 [PMID: 29741897] | ↑ activates | Mechanistic | DGIdb | |
| FLUOCINONIDE | ↑ activates | Mechanistic | DGIdb | |
| MAPRACORAT | ↑ activates | Mechanistic | DGIdb | |
| CLOBETASOL PROPIONATE | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL210411 | ? unclear | Mechanistic | DGIdb | |
| FLUOCINOLONE ACETONIDE | ↑ activates | Mechanistic | DGIdb | |
| BETAMETHASONE | ↑ activates | Mechanistic | DGIdb | |
| BECLOMETHASONE DIPROPIONATE | ↑ activates | Mechanistic | DGIdb | |
| FLUNISOLIDE ANHYDROUS | ↑ activates | Mechanistic | DGIdb | |
| CORTISONE ACETATE | ↑ activates | Mechanistic | DGIdb |
Showing top 40 of 264 agents ranked by evidence tier.
PDCD1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CAMRELIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| AMP-224 | ? unclear | Mechanistic | DGIdb | |
| PEMBROLIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| SERPLULIMAB | ? unclear | Mechanistic | DGIdb | |
| ENLONSTOBART | ? unclear | Mechanistic | DGIdb | |
| CEMIPLIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| CT-011 | ? unclear | Mechanistic | DGIdb | |
| SASANLIMAB | ? unclear | Mechanistic | DGIdb | |
| PUCOTENLIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| TISLELIZUMAB | ? unclear | Mechanistic | DGIdb | |
| TEBOTELIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| CADONILIMAB | ? unclear | Mechanistic | DGIdb | |
| SPARTALIZUMAB | ? unclear | Mechanistic | DGIdb | |
| MEDI0680 | ? unclear | Mechanistic | DGIdb | |
| AUNP-12 | ? unclear | Mechanistic | DGIdb | |
| DOSTARLIMAB | ? unclear | Mechanistic | DGIdb | |
| TORIPALIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| CC-90006 | ? unclear | Mechanistic | DGIdb | |
| CETRELIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PROGRAMMED CELL DEATH 1 LIGAND 1 | ? unclear | Mechanistic | DGIdb | |
| ANTI-PD-1 MONOCLONAL ANTIBODY SYM021 | ? unclear | Mechanistic | DGIdb | |
| CS-1003 | ↓ inhibits | Mechanistic | DGIdb | |
| EZABENLIMAB | ? unclear | Mechanistic | DGIdb | |
| PROLGOLIMAB | ? unclear | Mechanistic | DGIdb | |
| LIPUSTOBART | ? unclear | Mechanistic | DGIdb | |
| PENPULIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| BALSTILIMAB | ? unclear | Mechanistic | DGIdb | |
| GEPTANOLIMAB | ? unclear | Mechanistic | DGIdb | |
| IVONESCIMAB | ? unclear | Mechanistic | DGIdb | |
| SINTILIMAB | ? unclear | Mechanistic | DGIdb | |
| LORIGERLIMAB | ? unclear | Mechanistic | DGIdb | |
| FINOTONLIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| RETIFANLIMAB | ? unclear | Mechanistic | DGIdb | |
| PUCOLENTIMAB | ? unclear | Mechanistic | DGIdb | |
| BINTRAFUSP ALFA | ? unclear | Mechanistic | DGIdb | |
| IPAROMLIMAB | ? unclear | Mechanistic | DGIdb | |
| PIMIVALIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| VUDALIMAB | ? unclear | Mechanistic | DGIdb | |
| APL-501 | ↓ inhibits | Mechanistic | DGIdb | |
| ZIMBERELIMAB | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 52 agents ranked by evidence tier.
PROC
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| LUSUTROMBOPAG | ? unclear | Mechanistic | DGIdb | |
| PROTHROMBIN COMPLEX CONCENTRATE | ? unclear | Mechanistic | DGIdb | |
| PROTEIN C CONCENTRATE (HUMAN) | ? unclear | Mechanistic | DGIdb | |
| PROGESTERONE | ? unclear | Mechanistic | DGIdb | |
| WARFARIN | ? unclear | Mechanistic | DGIdb | |
| VITAMIN K3 | ? unclear | Mechanistic | DGIdb | |
| ESTRADIOL VALERATE | ? unclear | Mechanistic | DGIdb | |
| COMPOUND 37 [PMID: 24418773] | ↓ inhibits | Mechanistic | DGIdb | |
| ANCROD | ? unclear | Mechanistic | DGIdb | |
| SYNTHETIC CONJUGATED ESTROGENS, A | ? unclear | Mechanistic | DGIdb | |
| AVATROMBOPAG | ? unclear | Mechanistic | DGIdb | |
| 3K3A-ACTIVATED PROTEIN C | ? unclear | Mechanistic | DGIdb | |
| SODIUM TETRADECYL SULFATE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL133326 | ↓ inhibits | Mechanistic | 23000.0 nM (IC50) | ChEMBL |
| CHEMBL559015 | ↓ inhibits | Mechanistic | 1800.0 nM (Ki) | ChEMBL |
| CHEMBL432306 | ↓ inhibits | Mechanistic | 3700.0 nM (IC50) | ChEMBL |
| CHEMBL330572 | ↓ inhibits | Mechanistic | 5200.0 nM (Ki) | ChEMBL |
| CHEMBL92530 | ↓ inhibits | Mechanistic | 18000.0 nM (Ki) | ChEMBL |
| CHEMBL93854 | ↓ inhibits | Mechanistic | 1970.0 nM (Ki) | ChEMBL |
| CHEMBL431267 | ↓ inhibits | Mechanistic | 11000.0 nM (Ki) | ChEMBL |
| CHEMBL96218 | ↓ inhibits | Mechanistic | 9500.0 nM (Ki) | ChEMBL |
| CHEMBL85757 | ↓ inhibits | Mechanistic | 12000.0 nM (Ki) | ChEMBL |
| CHEMBL328893 | ↓ inhibits | Mechanistic | 8000.0 nM (Ki) | ChEMBL |
| CHEMBL431281 | ↓ inhibits | Mechanistic | 4200.0 nM (Ki) | ChEMBL |
| CHEMBL93151 | ↓ inhibits | Mechanistic | 5500.0 nM (Ki) | ChEMBL |
| CHEMBL107627 | ↓ inhibits | Mechanistic | 13500.0 nM (Ki) | ChEMBL |
| CHEMBL107911 | ↓ inhibits | Mechanistic | 94000.0 nM (Ki) | ChEMBL |
| CHEMBL107282 | ↓ inhibits | Mechanistic | 39000.0 nM (Ki) | ChEMBL |
| CHEMBL319035 | ↓ inhibits | Mechanistic | 33000.0 nM (Ki) | ChEMBL |
| CHEMBL322901 | ↓ inhibits | Mechanistic | 12000.0 nM (Ki) | ChEMBL |
| CHEMBL322165 | ↓ inhibits | Mechanistic | 10300.0 nM (Ki) | ChEMBL |
| CHEMBL107392 | ↓ inhibits | Mechanistic | 15200.0 nM (Ki) | ChEMBL |
| CHEMBL352039 | ↓ inhibits | Mechanistic | 6000.0 nM (IC50) | ChEMBL |
| CHEMBL70328 | ↓ inhibits | Mechanistic | 15000.0 nM (Ki) | ChEMBL |
| CHEMBL98472 | ↓ inhibits | Mechanistic | 6560.0 nM (IC50) | ChEMBL |
| CHEMBL98858 | ↓ inhibits | Mechanistic | 73000.0 nM (IC50) | ChEMBL |
| CHEMBL327600 | ↓ inhibits | Mechanistic | 1200.0 nM (Ki) | ChEMBL |
| CHEMBL93796 | ↓ inhibits | Mechanistic | 7000.0 nM (Ki) | ChEMBL |
| CHEMBL331943 | ↓ inhibits | Mechanistic | 2400.0 nM (Ki) | ChEMBL |
| DABIGATRAN | ↓ inhibits | Mechanistic | 20930.0 nM (Ki) | ChEMBL |
Showing top 40 of 168 agents ranked by evidence tier.
THBD
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| GINKGO | ? unclear | Mechanistic | DGIdb | |
| ALPROSTADIL | ? unclear | Mechanistic | DGIdb | |
| LEVOTHYROXINE SODIUM | ? unclear | Mechanistic | DGIdb | |
| SIMVASTATIN | ? unclear | Mechanistic | DGIdb | |
| CILOSTAZOL | ? unclear | Mechanistic | DGIdb | |
| CURCUMIN | ? unclear | Mechanistic | DGIdb |
TLR4
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| NEOCEPTIN-3 | ↑ activates | Mechanistic | DGIdb | |
| CISPLATIN | ? unclear | Mechanistic | DGIdb | |
| PARIDIPRUBART | ? unclear | Mechanistic | DGIdb | |
| ACETAMINOPHEN | ? unclear | Mechanistic | DGIdb | |
| RESATORVID | ? unclear | Mechanistic | 680.0 nM (IC50) | DGIdb |
| SAQUINAVIR | ? unclear | Mechanistic | DGIdb | |
| CRX-555 | ↑ activates | Mechanistic | DGIdb | |
| TLR AGONIST CADI-05 | ? unclear | Mechanistic | DGIdb | |
| INFLIXIMAB | ? unclear | Mechanistic | DGIdb | |
| ADJUVANT | ? unclear | Mechanistic | DGIdb | |
| LPS | ↑ activates | Mechanistic | DGIdb | |
| FOLIC ACID | ? unclear | Mechanistic | DGIdb | |
| DEHYDRATED ALCOHOL | ? unclear | Mechanistic | DGIdb | |
| ERITORAN TETRASODIUM | ↓ inhibits | Mechanistic | 1.5 nM (IC50) | DGIdb |
| NELFINAVIR | ? unclear | Mechanistic | DGIdb | |
| DEFOSLIMOD | ? unclear | Mechanistic | DGIdb | |
| PERTUSSIS VACCINE | ? unclear | Mechanistic | DGIdb | |
| METHOTREXATE | ? unclear | Mechanistic | 1040.0 nM (IC50) | DGIdb |
| GSK1795091 | ↑ activates | Mechanistic | DGIdb | |
| G100 | ? unclear | Mechanistic | DGIdb | |
| ERITORAN | ? unclear | Mechanistic | 1.5 nM (IC50) | DGIdb |
| RITONAVIR | ? unclear | Mechanistic | DGIdb | |
| PREDNISOLONE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL382272 | ↓ inhibits | Mechanistic | 350.0 nM (IC50) | ChEMBL |
| CHEMBL200140 | ↓ inhibits | Mechanistic | 250.0 nM (IC50) | ChEMBL |
| CHEMBL200667 | ↓ inhibits | Mechanistic | 80.0 nM (IC50) | ChEMBL |
| CHEMBL200398 | ↓ inhibits | Mechanistic | 160.0 nM (IC50) | ChEMBL |
| POLYMYXIN B | ↓ inhibits | Mechanistic | 1230.0 nM (IC50) | ChEMBL |
| CHEMBL535384 | ↓ inhibits | Mechanistic | 4500.0 nM (IC50) | ChEMBL |
| CHEMBL537642 | ↓ inhibits | Mechanistic | 6110.0 nM (IC50) | ChEMBL |
| CHEMBL537866 | ↓ inhibits | Mechanistic | 10500.0 nM (IC50) | ChEMBL |
| CHEMBL537865 | ↓ inhibits | Mechanistic | 9400.0 nM (IC50) | ChEMBL |
| CHEMBL537645 | ↓ inhibits | Mechanistic | 61400.0 nM (IC50) | ChEMBL |
| CHEMBL534488 | ↓ inhibits | Mechanistic | 27600.0 nM (IC50) | ChEMBL |
| CHEMBL538329 | ↓ inhibits | Mechanistic | 35600.0 nM (IC50) | ChEMBL |
| CHEMBL535159 | ↓ inhibits | Mechanistic | 59100.0 nM (IC50) | ChEMBL |
| CHEMBL448191 | ~ modulates | Mechanistic | ChEMBL | |
| CHEMBL507938 | ~ modulates | Mechanistic | ChEMBL | |
| CHEMBL505526 | ↓ inhibits | Mechanistic | 2.4 nM (IC50) | ChEMBL |
| CHEMBL501231 | ↓ inhibits | Mechanistic | 5.3 nM (IC50) | ChEMBL |
Showing top 40 of 205 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| DICLOFENAC SODIUM | ? unclear | Mechanistic | DGIdb | |
| RDP58 | ? unclear | Mechanistic | DGIdb | |
| METHYLENE BLUE | ? unclear | Mechanistic | DGIdb | |
| ORTATAXEL | ? unclear | Mechanistic | DGIdb | |
| CERTOLIZUMAB PEGOL | ↓ inhibits | Mechanistic | DGIdb | |
| OZORALIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| THALIDOMIDE | ? unclear | Mechanistic | DGIdb | |
| HUANG LIAN | ? unclear | Mechanistic | DGIdb | |
| GOLIMUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| CYCLOSPORINE | ? unclear | Mechanistic | DGIdb | |
| DOCETAXEL ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| HALOFUGINONE | ? unclear | Mechanistic | DGIdb | |
| ETANERCEPT | ↓ inhibits | Mechanistic | DGIdb | |
| ISIS 104838 | ? unclear | Mechanistic | DGIdb | |
| GEMCITABINE | ? unclear | Mechanistic | DGIdb | |
| INDOMETHACIN | ? unclear | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ? unclear | Mechanistic | DGIdb | |
| DIDANOSINE | ? unclear | Mechanistic | DGIdb | |
| 5,7-DIHYDROXY-4-METHYLCOUMARIN | ? unclear | Mechanistic | DGIdb | |
| SOBLIDOTIN | ? unclear | Mechanistic | DGIdb | |
| STAVUDINE | ? unclear | Mechanistic | DGIdb | |
| CISPLATIN | ? unclear | Mechanistic | DGIdb | |
| MEROPENEM ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| AMPHOTERICIN B LIPOSOMAL | ? unclear | Mechanistic | DGIdb | |
| MIDAZOLAM HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| RIFAMPIN | ? unclear | Mechanistic | DGIdb | |
| AVX-470 | ? unclear | Mechanistic | DGIdb | |
| KETOROLAC TROMETHAMINE | ? unclear | Mechanistic | DGIdb | |
| PRAZOSIN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| RISPERIDONE | ? unclear | Mechanistic | DGIdb | |
| BENZO[E]PYRENE | ? unclear | Mechanistic | DGIdb | |
| ETHAMBUTOL HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| REMTOLUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| SPIRONOLACTONE | ? unclear | Mechanistic | DGIdb | |
| OMEPRAZOLE | ? unclear | Mechanistic | DGIdb | |
| CARBOPLATIN | ? unclear | Mechanistic | DGIdb | |
| MITOMYCIN C ANALOG KW-2149 | ? unclear | Mechanistic | DGIdb | |
| NAFAMOSTAT | ? unclear | Mechanistic | DGIdb | |
| ABBV-3373 | ~ modulates | Mechanistic | DGIdb | |
| BACILLUS CALMETTE-GUERIN ANTIGEN | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 287 agents ranked by evidence tier.
Clinical Trials
Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Sepsis: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.
The goal of this clinical trial is to assess whether clarithromycin, given as an adjunct to standard-of-care antibiotic therapy, can reduce the risk of new infections and secondary sepsis in adult patients hospitalized with community-acquired pneumonia (CAP), sepsis, and sepsis-induced immunoparalys...
Norwegian guidelines for empirical antibiotic therapy in suspected community acquired sepsis recommend the combination of narrow spectrum betalactam and aminoglycoside as the first choice, but broad spectrum betalactams are considered equally appropriate, effective, and safe. However, fear of renal ...
This study investigated whether giving the probiotic Lactiplantibacillus plantarum DAD-13 to sepsis patients in the intensive care unit (ICU) could help reduce inflammation and improve bowel function. A total of 30 adult ICU patients with sepsis were randomly assigned to receive either the probiotic...
Preterm infants are born at less than 37 weeks of pregnancy. Sometimes a break or tear in the fluid filled bag that surrounds and protects the infant during pregnancy leads to an untimely birth. This state puts the infant at risk of serious condition called sepsis. Sepsis is a condition in which bod...
The goal of this clinical trial is to demonstrate the clinical benefit of early intervention with meropenem in adult patients of both sexes with suspected infection and risk of sepsis. The primary objective is to evaluate the clinical benefit of a protein called Pancreatic Stone Protein (PSP), which...
PALETTE is a perpetual adaptive platform to efficiently study sepsis interventions within 'treatable traits' in all-ages patients enabling prompt evaluation of pandemic treatments. Treatable traits, therapeutic targets identified by phenotypes or endotypes (defined by biological mechanism or by trea...
Patients hospitalized in ICU with sepsis (infection with life-threatening organ dysfunction according to sepsis 3.0 definitions) or septic shock presumably due to MDR-GNB (multidrug resistant Gram-negative bacteria). The study will be a prospective multicentre, randomized, open-label comparative con...
Sepsis is a life-threatening illness caused by an abnormal response to infection. Some people with sepsis have reduced immune function, which may make recovery more difficult. This study will examine whether adding thymalfasin, also called thymosin alpha-1, to usual sepsis care improves recovery of ...
The goal of this clinical trial is to learn if preterm infants who are prescribed antibiotics shortly after birth can safely receive a shorter course of antibiotics (24 to 36 hours instead of 48 hours). The main questions it aims to answer are: * Does short-course ampicillin provide high enough leve...
Sepsis is a life-threatening organ dysfunction caused by the maladjusted response of the host to infection. It is a clinical syndrome with high mortality. Studies have confirmed that many cytokines play a vital role in the pathogenesis of sepsis. Ulinastatin (UTI) is a glycoprotein that exists in hu...
Sepsis is a life-threatening condition that occurs when the body's response to an infection becomes overwhelming and damages its own organs. It is one of the leading causes of death in critically ill (very sick) patients worldwide. Despite advances in antibiotics, intensive care, and life-support te...
The primary objective of the IMPACT-NAC trial is to assess the effects of N-acetylcysteine on survival and hospital length of stay in adults admitted to the emergency department with acute infection or sepsis and evidence of liver dysfunction. The main question it aims to answer is: does N-acetylcys...
This study will enroll adults aged 18 to 80 years diagnosed with sepsis due to a suspected or confirmed bacterial infection, within 7 days of being admitted to the hospital, and who have also developed acute kidney injury within 72 hours of the onset of sepsis. Eligible participants will be randomly...
The long-term goal is to test the clinical efficacy of senolytic therapies to reduce progression to and severity of sepsis in older patients. The central hypothesis is that a threshold burden of SnCs predisposes to a SASP mediated dysfunctional response to PAMPs, contributing to a disproportionate b...
This study is being done to determine if early administration of Midodrine can improve outcomes by maintaining a higher mean blood pressure off of intravenous medications. Researchers want to see if Midodrine can help people with sepsis need fewer vasopressors, which could mean shorter hospital stay...
Agents Found By Disease-Level Search
Searched directly from “Sepsis” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 12-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
47 agents shown (approved or with trial evidence) — 43 not found by the gene-target search above.
MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)NOT in gene-target list
Replenish ProteinNOT in gene-target list
Standard proteinNOT in gene-target list
Multifaceted de-implementation strategy to reduce vancomycin overuseNOT in gene-target list
fosmanogepix (APX001)NOT in gene-target list
Antibiotic
In vitro determination of non-carbonic buffer powerNOT in gene-target list
Classic description of acid-base statusNOT in gene-target list
trovafloxacin and levofloxacinNOT in gene-target list
REGN7544NOT in gene-target list
PBNOT in gene-target list
SOPs for decision-making and communicationNOT in gene-target list
Chlorhexidine Gluconate Skin CleanserNOT in gene-target list
Mild Soap Skin CleanserNOT in gene-target list
HealthPatchNOT in gene-target list
ViSi MobileNOT in gene-target list
Pediatric eCARTNOT in gene-target list
Intravenous human immunoglobulinNOT in gene-target list
AlbuminNOT in gene-target list
Propafenone i.v.NOT in gene-target list
Amiodarone i.v.NOT in gene-target list
Antibody-Drug ConjugateNOT in gene-target list
Antineoplastic and immunomodulating agents other than Antibody-Drug ConjugateNOT in gene-target list
Talactoferrin alfaNOT in gene-target list
Soluble Immune checkpoint levelsNOT in gene-target list
HaloperidolNOT in gene-target list
Ziprasidone
Interferon gammaNOT in gene-target list
Vitamin CNOT in gene-target list
Dextrose 5% in waterNOT in gene-target list
Quantiferon CMV (assay that determine the presence of CMV-specific T lymphocytes).NOT in gene-target list
Piperacillin-tazobactamNOT in gene-target list
Thoracic duct drainageNOT in gene-target list
sodium selenite pentahydrateNOT in gene-target list
Anisodamine hydrobromide combined with heparinNOT in gene-target list
Fortified Pasteurized Donor Human Milk supplementNOT in gene-target list
Preterm Formula supplementNOT in gene-target list
Sepsis Transition And Recovery (STAR)NOT in gene-target list
Dobutamine
Dexmedetomidine HydrochlorideNOT in gene-target list
Esmolol Hydrochloride
C1-esterase inhibitorNOT in gene-target list
Winclove 607NOT in gene-target list
Intravenous fluidNOT in gene-target list
taurolidineNOT in gene-target list
Chlorhexidine Topical CreamNOT in gene-target list
Methylated SpiritNOT in gene-target list
Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.